Harpoon Therapeutics, Inc

150 articles about Harpoon Therapeutics, Inc

• Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/10/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences - Nov 09, 2021

  11/9/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that management will participate in two upcoming virtual investor conferences.

• Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

  11/4/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology Annual Meeting and Exposition.

• Harpoon Therapeutics Announces Change to Management Team and Board of Directors

  10/26/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Julie Eastland has been named President and Chief Executive Officer, effective November 8, 2021.

• Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

  10/5/2021

  Harpoon Therapeutics, Inc. today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

• Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences in September 2021

  9/2/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual investor conferences.

• Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences - Aug 03, 2021

  8/3/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences

• Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

  6/4/2021

  Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment duration All four clinical programs demonstrate half-life extension, target engagement and T cell activation Cytokine release syndrome observed and manageable, with low incidence of severe CRS Management to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT

• Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

  6/4/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

• Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual MeetingManagement to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021

  5/19/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting beginning on June 4,2021.

• Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/6/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

  4/28/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit.

• Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

  4/10/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced the availability of three poster presentations at the American Association for Cancer Research Annual Meeting.

• Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

  3/24/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles.

• Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

  3/11/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting

• Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/10/2021

  Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer

• Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

  3/9/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33 rd Annual Roth Conference.

• Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

  3/4/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021.

• Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

  2/17/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10 th Annual Global Healthcare Conference. The discussion will take place on Wednesday, February 24, 2021 at 4:20 p.m. ET (1:20 p.m. PT).